AlphaStar Capital Management’s Humacyte HUMA Stock Holding History

AlphaStar Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,767	Closed	-$22.5K	–	265
2025 Q2	$22.5K	Hold	10,767	–	–	﹤0.01%	357
2025 Q1	$18.4K	Hold	10,767	–	–	﹤0.01%	184
2024 Q4	$54.4K	Hold	10,767	–	–	0.01%	200
2024 Q3	$58.6K	Hold	10,767	–	–	﹤0.01%	367
2024 Q2	$51.7K	Hold	10,767	–	–	﹤0.01%	309
2024 Q1	$33.5K	Hold	10,767	–	–	﹤0.01%	285
2023 Q4	$30.6K	Hold	10,767	–	–	﹤0.01%	267
2023 Q3	$31.5K	Hold	10,767	–	–	﹤0.01%	244
2023 Q2	$30.8K	Hold	10,767	–	–	﹤0.01%	251
2023 Q1	$33.3K	Hold	10,767	–	–	﹤0.01%	262
2022 Q4	$22.7K	Hold	10,767	–	–	﹤0.01%	315
2022 Q3	$35K	Hold	10,767	–	–	﹤0.01%	304
2022 Q2	$35K	Hold	10,767	–	–	﹤0.01%	344
2022 Q1	$76K	Buy	+10,767	New	+$62.7K	0.01%	373

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AlphaStar Capital Management's HUMA Position: Q3 2025 in Review

AlphaStar Capital Management sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 10,767 shares — an estimated $22.5K sold.

AlphaStar Capital Management first reported a position in HUMA in Q1 2022 and held it in 14 quarters. The position peaked at $76K in Q1 2022. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

AlphaStar Capital Management reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
AlphaStar Capital Management sold 10,767 Humacyte shares in Q3 2025, an estimated $22.5K.
AlphaStar Capital Management first reported a position in Humacyte in Q1 2022 and held it in 14 quarters.
AlphaStar Capital Management's Humacyte position peaked at $76K in Q1 2022.
141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on AlphaStar Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.